Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants

Transplant Proc. 2001 Feb-Mar;33(1-2):1015-7. doi: 10.1016/s0041-1345(00)02310-1.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antibodies, Monoclonal / blood
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Daclizumab
  • Drug Administration Schedule
  • Female
  • Graft Rejection / prevention & control*
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin G / therapeutic use*
  • Immunosuppression Therapy
  • Immunosuppressive Agents / blood
  • Immunosuppressive Agents / therapeutic use*
  • Intestine, Small / transplantation*
  • Male
  • Organ Transplantation*
  • Remission Induction

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Daclizumab